Tiziana Life Sciences Ltd (TLSA)Healthcare | Biotechnology | London, United Kingdom | NasdaqCM
1.01 USD
-0.07
(-6.481%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.05 +0.04 (3.564%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:37 a.m. EDT
The immediate outlook is driven by a massive divergence between the company's precarious financial reality and the aggressive optimism of the options market. While the balance sheet is fragile, with negative free cash flow, high debt-to-equity, and no revenue generation, the recent clinical data showing reduced neuroinflammation in MSA trials has ignited a speculative frenzy. This is confirmed by the options flow, which is entirely one-sided bullish with zero put activity, suggesting traders are betting on a binary event or a major catalyst rather than a steady recovery. However, the long-term investment case remains neutral due to the lack of a sustainable business model; the company burns cash, relies on capital raises to fund trials, and has no dividend history. The recent price action shows some resilience, bouncing off lows, but without a proven path to profitability or a fortress balance sheet, this remains a high-risk speculative play dependent on future trial results rather than a fundamental buy. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.095135 |
| AutoARIMA | 0.095211 |
| MSTL | 0.104324 |
| AutoTheta | 0.105432 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.51 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.337 |
| Excess Kurtosis | -1.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 876.923 |
| Market Cap | 128,531,720 |
| Forward P/E | -5.06 |
| Beta | 0.46 |
| Previous Name | Tiziana Life Sciences PLC |
| Website | https://www.tizianalifesciences.com |
As of Aug. 22, 2026, 2:37 a.m. EDT: Speculators are overwhelmingly bullish, evidenced by a complete absence of put activity and heavy open interest in out-of-the-money calls. The call chain shows significant positioning at strikes far above the current price, indicating a strong expectation of a substantial upward move, while the lack of protective puts suggests traders are not hedging against downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.40659338 |
| Address1 | 14/15 Conduit Street |
| All Time High | 12.17 |
| All Time Low | 0.41 |
| Ask | 1.1 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 1,110,380 |
| Average Daily Volume3 Month | 538,787 |
| Average Volume | 538,787 |
| Average Volume10Days | 1,110,380 |
| Beta | 0.463 |
| Bid | 1.01 |
| Bid Size | 1 |
| Book Value | 0.0 |
| City | London |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.01 |
| Current Ratio | 0.763 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.08 |
| Day Low | 0.998 |
| Debt To Equity | 876.923 |
| Display Name | Tiziana Life Sciences |
| Earnings Timestamp End | 1,752,004,800 |
| Earnings Timestamp Start | 1,750,708,800 |
| Ebitda | -21,120,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.595 |
| Enterprise Value | 118,158,472 |
| Eps Current Year | -0.119 |
| Eps Forward | -0.19961944 |
| Eps Trailing Twelve Months | -0.16 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.0978 |
| Fifty Day Average Change | -0.087800026 |
| Fifty Day Average Change Percent | -0.07997816 |
| Fifty Two Week Change Percent | -40.65934 |
| Fifty Two Week High | 2.35 |
| Fifty Two Week High Change | -1.3399999 |
| Fifty Two Week High Change Percent | -0.5702128 |
| Fifty Two Week Low | 0.87 |
| Fifty Two Week Low Change | 0.13999999 |
| Fifty Two Week Low Change Percent | 0.16091952 |
| Fifty Two Week Range | 0.87 - 2.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,542,724,200,000 |
| Float Shares | 61,886,576 |
| Forward Eps | -0.19961944 |
| Forward P E | -5.0596275 |
| Free Cashflow | -5,476,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 10 |
| Fullday Change | -0.0700001 |
| Fullday Change Percent | -6.48149 |
| Fullday Price | 1.046 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.47647 |
| Held Percent Institutions | 0.01938 |
| Implied Shares Outstanding | 127,259,131 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,596,153,600 |
| Last Split Factor | 2,499:1000 |
| Long Business Summary | Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom. |
| Long Name | Tiziana Life Sciences Ltd |
| Market | us_market |
| Market Cap | 128,531,720 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_261234197 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -18,431,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 137,439,861 |
| Number Of Analyst Opinions | 1 |
| Open | 1.07 |
| Operating Cashflow | -12,847,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 44 20 7495 2379 |
| Post Market Change | 0.036000013 |
| Post Market Change Percent | 3.5643578 |
| Post Market Price | 1.046 |
| Post Market Time | 1,787,959,805 |
| Prev Name | Tiziana Life Sciences PLC |
| Previous Close | 1.08 |
| Price Eps Current Year | -8.487394 |
| Price Hint | 4 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.722 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0700001 |
| Regular Market Change Percent | -6.48149 |
| Regular Market Day High | 1.08 |
| Regular Market Day Low | 0.998 |
| Regular Market Day Range | 0.998 - 1.08 |
| Regular Market Open | 1.07 |
| Regular Market Previous Close | 1.08 |
| Regular Market Price | 1.01 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 565,521 |
| Return On Assets | -1.1596199 |
| Return On Equity | -9.24323 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 127,259,131 |
| Shares Percent Shares Out | 0.0134000005 |
| Shares Short | 1,699,378 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,245,738 |
| Short Name | Tiziana Life Sciences Ltd |
| Short Percent Of Float | 0.0467 |
| Short Ratio | 2.36 |
| Source Interval | 15 |
| Symbol | TLSA |
| Target High Price | 9.063342 |
| Target Low Price | 9.063342 |
| Target Mean Price | 9.063342 |
| Target Median Price | 9.063342 |
| Total Cash | 4,010,000 |
| Total Cash Per Share | 0.033 |
| Total Debt | 456,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.35625 |
| Two Hundred Day Average Change | -0.34625006 |
| Two Hundred Day Average Change Percent | -0.25529957 |
| Type Disp | Equity |
| Volume | 565,521 |
| Website | https://www.tizianalifesciences.com |
| Zip | W1S 2XJ |